65,437 trials
Chronic Pain · Opioid Addiction · Symptomatic Hypogonadism
Primary: Number of Participants Demonstrating Abstinence — 5; 4 Participants
Intubation; Difficult · Cervical Spine Injury
Primary: Head Motion - Extension or Flexion — 16.5; 17.7 degrees of extension
Cocaine Dependence
Primary: Cocaine Use — 18.82; 14.81; 15.68; 14.85 Days
Ventilator-acquired Pneumonia
Primary: Percentage of Patients With Tracheal Bacterial Colonization — 8; 7; 9 percentage of tracheal colonization
Glomerulosclerosis, Focal Segmental
Primary: Number of Participants Meeting the Definition of Responder for Reduction in Proteinuria at the Indicated Time Points — 0; 1; 0; 0 Participants
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 0.87 percentage
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Number of Participants With Composite of Stroke/MI/Death — 442; 497 Participants — p=0.0670
Surgery · Healthy
Primary: Accuracy of Sensor — 0.98 g/dL
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
Healthy · Surgery
Primary: Accuracy of Sensor by Arms Calculation — 0.9 g/dL
Lung Cancer
Primary: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen — 57 Participants
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear — 60.66; 56.74; 59.54; 62.22 percentage of parabasal cells
Influenza
Primary: Number of Participants Who Received the Influenza Vaccine — 59; 37; 40 Participants
Arthritis, Rheumatoid
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (NSAEs) — 4; 24 participants